Bordetella bronchiseptica aroA mutant as a live vaccine vehicle for heterologous porcine circovirus type 2 major capsid protein expression.
Porcine circovirus type 2 (PCV2) infections cause important respiratory diseases in the pig industry and are associated with many bacterial, mycoplasmal, and viral complications. In this study, a heterologous PCV2 major capsid protein (MCP) was expressed in the Bordetella bronchiseptica aroA mutant strain (BBS-MCP) and used as a live vaccine vehicle. Mice and pigs were immunized with live BBS-MCP via the intranasal route. The antibodies against MCP were induced successfully in the serum as determined by ELISA. In the PCV2 challenge experiment, viral DNA was removed successfully from the lymph nodes of pigs vaccinated with live BBS-MCP. Overall, BBS-MCP is believed to be a good candidate for the development of a live-attenuated vaccine against PCV2 infections.
Kim
Taejung
T
Biotherapy Human Resources Center, Chonnam National University, Gwangju, Republic of Korea.
Toan
Nguyen Tat
NT
Seo
Jayoung
J
Jung
Bockgie
B
Lee
Jaeil
J
Lee
Bongjoo
B
D000281:Administration, Intranasal; D000818:Animals; D016950:Bordetella bronchiseptica / Q000235:genetics*; D036022:Capsid Proteins / Q000276:immunology*; D017925:Circovirus / Q000276:immunology*; D003001:Cloning, Molecular; D015964:Gene Expression Regulation, Bacterial; D051379:Mice; D009154:Mutation; D053570:Porcine Postweaning Multisystemic Wasting Syndrome / Q000517:prevention & control / Q000821:virology; D013552:Swine; D014764:Viral Proteins / Q000235:genetics / Q000276:immunology; D014765:Viral Vaccines / Q000008:administration & dosage / Q000276:immunology*
D036022:Capsid Proteins; D014764:Viral Proteins; D014765:Viral Vaccines